Portfolio news - Archive
08.12.2015 Pieris Pharmaceuticals Announces First Cancer Immunotherapy Collaboration 
more...
30.11.2015 Pieris Pharmaceuticals Achieves Payment Milestone in Sanofi Collaboration more...
19.11.2015 Pieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program more...
30.09.2015 Positive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program at ERS and Company Strengthens Management Team more...
15.09.2015 Pieris Pharmaceuticals' Collaborator Presents Promising Preclinical Data on Tetraspecific Infectious Disease Anticalin Program at ASM Conference more...
18.08.2015 Pieris Pharmaceuticals Appoints Louis A. Matis, M.D., as Chief Development Officer more...
28.07.2015 Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock more...
08.07.2015 Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics more...
06.07.2015 Pieris Pharmaceuticals Closes Public Offering of Common Stock more...
30.06.2015 Pieris Pharmaceuticals Prices Public Offering of Common Stock more...
10.06.2015 Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia more...
21.05.2015 Nabriva Therapeutics appoints Elyse Seltzer, MD, as Chief Medical Officer more...
19.05.2015 Pieris Pharmaceuticals to Present Data on Novel Anti-CD137 and HER2 Bispecific Immuno-Oncology Program at UBS Global Healthcare Conference more...
14.05.2015 Pieris Pharmaceuticals Appoints Immuno-Oncology Expert, Holbrook Kohrt, M.D., Ph.D., to Spearhead Immuno-Oncology Efforts and Initiates Research Collaboration with Leading Cancer Research Center more...
12.05.2015 Pieris Pharmaceuticals Appoints Former Celgene and Sanofi Executive,
Jean-Pierre Bizzari, M.D., to its Board of Directors more...
07.04.2015 Nabriva Therapeutics announces financing of up to $120 million to advance clinical development of new class of antibiotic more...
30.03.2015 Pieris Pharmaceuticals and The University of Melbourne Receive Research Grant to Advance Immunological Diseases Program more...
04.03.2015 Pieris to Present at Two Upcoming Conferences BIO-Europe Spring 2015 & the 27th Annual ROTH Conference more...
04.03.2015 Agendia’s BluePrint Molecular Subtyping Assay Highlighted at the 32nd Annual Miami Breast Cancer Conference more...
10.02.2015 Agendia Receives New FDA Clearance for MammaPrint FFPE Breast Cancer Test more...
29.01.2015 Nabriva Therapeutics strengthens Board and Management Team more...
18.12.2014 Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million more...
11.12.2014 Pieris Initiates Phase I Clinical Trial for Anticalin® to Treat Anemia more...
08.12.2014 Pieris Achieves GLP Tox Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics more...
04.12.2014 Agendia’s MammaPrint and BluePrint Tests to be highlighted at San Antonio Breast Cancer Symposium more...
01.12.2014 Pieris Achieves Second Preclinical Milestone Payment in Sanofi Collaboration more...
12.11.2014 Pieris Appoints Michael Richman as Supervisory Board Member more...
09.10.2014 Agendia Breast Cancer Test for Molecular Subtyping Improves Match of Therapy to Patient, Study Finds more...
08.10.2014 Nabriva Therapeutics announces qualified infectious disease product and fast track status granted by the US FDA for lefamulin more...
02.10.2014 Agendia Board of Directors Appoints Jan Egberts, M.D., as CEO more...
15.09.2014 Agendia Test for Molecular Subtyping of Breast Cancer Is a Better Guide
to Pre-Surgical Treatment, Study Finds more...
08.09.2014 Nabriva Therapeutics presented data on lead pleuromutilin antibiotic lefamulin (BC-3781) at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington DC more...
03.09.2014 Nabriva Therapeutics Appoints Dr Colin Broom As Chief Executive Officer more...
02.09.2014 Agendia Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment more...
04.08.2014 Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines more...
31.07.2014 Agendia Co-Founder and
CSO Develops Method to Identify Women Who Will Benefit from Tamoxifen Therapy for Breast Cancer more...
16.07.2014 Agendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer more...
23.06.2014 Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics more...
10.06.2014 Value of Breast Cancer Molecular Subtyping Documented by Independent Study Comparing Genomic Tests at ASCO 2014 Meeting more...
09.06.2014 African-American Women More Likely to Be Diagnosed with Higher Risk Breast Cancer more...
12.05.2014 Nabriva Therapeutics presents extended spectrum pleuromutilin antibiotics at the 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona more...
07.05.2014 Molecular Subtyping with Agendia Tests Can Provide Better Guidance for Breast Cancer Treatment, New Research Reports more...
24.04.2014 Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development more...
26.03.2014 Agendia Announces New Data at European Breast Cancer Conference that Further Supports Use of MammaPrint and BluePrint Tests more...
11.03.2014 Agendia Co-Founder Awarded EU Prize for Women Innovators more...
11.03.2014 Agendia Test for Molecular Subtyping of Breast Cancer Shown to Better Identify Risk of Disease Recurrence more...
17.02.2014 Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome more...
10.02.2014 Pieris Achieves Preclinical Milestone Payment in Sanofi Collaboration more...
30.01.2014 Agendia’s MammaPrint & BluePrint Tests for Breast Cancer Highlighted at Personalized Medicine Conference more...
27.01.2014 Nabriva Therapeutics Receives ZIT Grant for Extended Spectrum Pleuromutilin (ESP) Program more...
13.01.2014 Pieris Achieves Fourth Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics more...
10.01.2014 Santaris Pharma A/S announce agreement with GlaxoSmithKline (GSK) to develop RNA-targeted medicines more...
09.01.2014 Santaris A/S announces worldwide discovery alliance for RNA-targeted medicines with Roche more...
08.01.2014 Isarna Therapeutics and Santaris Pharma Announce License Agreement for the Development of Next Generation Oligonucleotides to Treat TGF-β-Mediated Diseases more...
08.01.2014 Santaris Pharma A/S Announces Appointment of J. Donald deBethizy as President and Chief Executive Officer more...
17.12.2013 Stelis Biopharma and Pieris Forge Alliance for Novel Anticalin® Therapeutics in Ophthalmology more...
25.11.2013 Pixium Vision raises €15 million led by Sofinnova Partners more...
12.11.2013 Pieris Receives Third Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics more...
28.10.2013 Santaris Pharma A/S resumes full ownership of cancer programs licensed to Enzon Pharmaceutical Inc. more...
21.10.2013 Horizon Pharma announces Clinical Data on AYOS(R) (Prednisone) Delayed-Release Tablets to be presented at the American College of Rheumatology Annual Meeting more...
16.10.2013 Zydus and Pieris Sign Broad Co-Development Alliance for Novel Anticalin® Therapeutics more...
13.09.2013 Nabriva Therapeutics Presented Data on Potency, Safety, Tolerability and Pharmacokinetics of Pleuromutilin Antibiotic BC-3781
more...
09 09.2013 Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
more...
27.08.2013 Santaris Pharma A/S Completes Enrollment in Phase 2 Clinical Trial of Miravirsen In Null Responders to Pegylated Interferon and Ribavirin for the Treatment of the Hepatitis C Virus more...
27.08.2013 Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence
more...
23.08.2013 Shire and Santaris extend their strategic alliance to discover and develop LNA-drugs in the rare genetic disease field
more...
08.07.2013 RaNA Therapeutics, Inc. and Santaris Pharma A/S announce agreement to develop RNA-targeted medicines that selectively activate protein expression
more...
03.06.2013 Agendia Appoints Peter W. Schineller as Chief Commercial Officer
more...
31.05.2013 Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
more...
29.05.2013 Horizon Pharma Announces Receipt of Fifth U.S. Patent Allowance for DUEXIS(R)
more...
23.05.2013 Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
more...
02.05.2013 Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
more...
18.04.2013 Pieris Achieves Second Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics
more...
16.04.2013 Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb for RNA-targeted medicines
more...
10.04.2013 Pieris and Sanofi Broaden Existing Collaboration
more...
27.03.2013 Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S’ Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials
more...
11.02.2013 Horizon Pharma Announces Preliminary Fourth Quarter and Full Year 2012 Revenues, Full U.S. Commercial Launch of RAYOS(R) (Prednisone) Delayed-Release Tablets and Approval of LODOTRA(R) in South Korea
more...
08.01.2013 Santaris Pharma A/S and miRagen Therapeutics Inc. expand worldwide strategic alliance to discover and develop LNA-drugs against disease causing microRNAs
more...
07.01.2013 USPTO Grants Santaris' Request for Inter-Partes Reexamination of Patent licensed to Regulus
more...
03.12.2012 Horizon Pharma Begins Initial Commercial Launch of RAYOS(R) (prednisone) Delayed-Release Tablets in the United States
more...
29.11.2012 Pieris Presents Data and Reveals Targets for Anticalin Bispecific PRS-190 at European Antibody Congress
more...
22.11.2012 Agendia announces discovery of a gene signature that predicts response to a broad range of cancer drugs
more...
09.10.2012 Pieris Achieves First Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics
more...
25.09.2012 Horizon Pharma Announces Exercise in Full of Overallotment Option and Completion of Public Offering of Common Stock and Warrants to Purchase Common Stock
more...
21.09.2012 Court Focuses Patent Suit on Santaris' Safe Harbor Defense
more...
20.09.2012 Horizon Pharma Prices $75 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
more...
20.08.2012 Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
more...
26.07.2012 Horizon Pharma Announces FDA Approval of RAYOS(R) (prednisone) Delayed-Release Tablets for Rheumatoid Arthritis and Multiple Additional Indications
more...
18.07.2012 Nabriva Therapeutics Announces Management Changes
more...
20.06.2012 Santaris Pharma raises $12 million in new private investment round
more...
01.06.2012 Forest Laboratories and Nabriva Therapeutics sign Agreement
more...
31.05.2012 Agendia Raises $65 Million in a Private Round of Equity Financing
more...
03.05.2012 Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury
more...
25.04.2012 Henrik Stage Appointed Interim CEO of Santaris Pharma A/S
more...
19.04.2012 Santaris Pharma A/S presents final Phase 2a study results for miravirsen showing dose-dependent, prolonged antiviral activity in Hepatitis C patients
more...
05.04.2012 Zalicus Discovers Novel Multi-Target Mechanism for the Treatment of Multiple Myeloma
more...
04.04.2012 Pieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin at the AACR Annual Meeting
more...
07.02.2012 Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin Program
more...
05.12.2011 Zalicus Initiates Phase 1 Clinical Trial of Z160
more...
30.11.2011 USPTO upholds key Santaris Pharma A/S LNA patents in two re-examination cases brought by Isis Pharmaceuticals
more...
29.11.2011 Horizon Pharma Announces U.S. Food and Drug Administration Acceptance of LODOTRA(R) New Drug Application for Review for the Treatment of Rheumatoid Arthritis
more...
15.11.2011 Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
more...
14.11.2011 NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
more...
08.11.2011 NeurogesX Reports Positive Phase 2 Results for NGX-1998 for Treatment of Postherpetic Neuralgia
more...
05.11.2011 Santaris Pharma A/S Phase 2a data of miravirsen shows dose-dependent, prolonged viral reduction of 2-3 logs HCV RNA after four-week treatment in Hepatitis C patients
more...
19.10.2011 Pieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin Pipeline Development
more...
19.10.2011 EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia
more...
03.10.2011 Santaris Pharma A/S to report new clinical data from miravirsen Phase 2a study to treat Hepatitis C in late-breaking oral presentation at the AASLD 2011 annual meeting
more...
03.10.2011 Agendia Successfully Completes Bi-Annual FDA Inspection
more...
26.09.2011 Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery demonstrates positive top-line results
26.09.2011 Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery demonstrates positive top-line results
more...
15.09.2011 Nabriva Therapeutics Presents Extended Phase II Results for Pleuromutilin Antibiotic BC-3781
more...
08.09.2011 NeurogesX Submits Supplemental New Drug Application for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
more...
10.08.2011 International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment
more...
08.08.2011 Last patient completes last visit in Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery
more...
08.08.2011 NeurogesX, Inc. Secures $20 Million Debt Facility
more...
28.07.2011 Horizon Pharma Announces Pricing of Its Initial Public Offering
more...
21.07.2011 Agendia Receives €1.27 Million in Funding from the EU’s Seventh Framework Programme
more...
09.06.2011 Agendia Announces Colorectal Cancer Research Collaboration with Leading Cancer Centers – MD Anderson Cancer Center and Netherlands Cancer Institute
more...
23.05.2011 Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin PRS-080 Hepcidin Antagonist Drug Program
more...
17.05.2011 Zalicus Selected to Join the NASDAQ Biotechnology Index
more...
11.05.2011 Santaris Pharma A/S advances a second drug from its cardiometabolic program, SPC4955, inhibiting apoB, into Phase 1 clinical trials for the treatment of high cholesterol
more...
10.05.2011 Agendia Announces Colorectal Cancer Collaboration with AstraZeneca and The Netherlands Cancer Institute
more...
09.05.2011 Action Pharma completes dosing in phase IIb clinical trial with AP214 to prevent acute kidney injury associated with cardiac surgery
more...
28.04.2011 NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
more...
25.04.2011 Horizon Pharma Receives FDA Approval of DUEXIS®
more...
18.04.2011 Nabriva Reports Positive Results from Phase II Trial of Pleuromutilin Antibiotic BC-3781 in ABSSSI
more...
12.04.2011 Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin® Therapeutics
more...
29.03.2011 Zalicus Granted Composition-of-Matter Patent for Synavive
more...
21.03.2011 New data published in Nature Genetics demonstrate that tiny LNA-based compounds developed by Santaris Pharma A/S inhibit entire disease-associated microRNA families
more...
28.02.2011 Santaris Pharma A/S obtains exclusive license from Mass General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders
more...
25.02.2011 Zalicus Publishes Data on Sodium Channel Compound in Pain Models
more...
22.02.2011 Agendia Receives Fifth FDA Clearance for Industry Leading MammaPrint® Assay
more...
22.02.2011 Pieris to Present Interim Data from the Phase I Clinical Trial of PRS-050 at Molecular Medicine Tri-Conference
more...
10.01.2011 Zalicus Announces Plans for Advancing Product Candidates
more...
10.01.2011 Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration
more...
10.01.2011 Nabriva completes recruitment for Phase II of pleuromutilin antibiotic BC-3781
more...
04.01.2011 Pfizer to Pay $14 Million to Use Santaris Technology
more...
22.12.2010 Intercell starts a Phase I clinical trial for a new vaccine to prevent Clostridium difficile infections
more...
20.12.2010 Agendia & Collaborators Publish Key MammaPrint Paper in Nature Cell Biology
more...
15.12.2010 Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test “ColoPrint”
more...
12.12.2010 Intercell provides update on clinical trials for the patch-based Travelers' Diarrhea vaccine
more...
24.11.2010 NeurogesX Appoints New Director to Board
more...
19.11.2010 NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
more...
11.11.2010 7TM Pharma successfully conducts clinical Phase I trial of its first in class peripheral CB1 receptor antagonist TM38837 demonstrating restriction from the human CNS
more...
08.11.2010 Action Pharma initiates phase IIb clinical trial with AP214
more...
02.11.2010 NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
more...
19.10.2010 Agendia Establishes Contract with Humana To Cover MammaPrint
more...
18.10.2010 NeurogesX to Pursue Expanded U.S. Label for Qutenza(R) (capsaicin) 8% Patch in HIV-Associated Neuropathy
more...
28.09.2010 Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics
more...
22.09.2010 Santaris Pharma A/S advances miravirsen, the first microRNA-targeted drug to enter clinical trials, into Phase 2 to treat patients infected with Hepatitis C virus
more...
15.09.2010 Nabriva Therapeutics’ Pleuromutilin Antibiotic BC-3781 Shows Therapeutic Potential for Skin and Lung Infections with both Oral and IV Dosing in Non-Clinical and Clinical Phase I Studies
more...
13.09.2010 Action Pharma obtains positive phase II results with AP214
more...
09.09.2010 CombinatoRx Changes Company Name to Zalicus Inc.
more...
05.08.2010 Agendia inaugurates new state-of-the-art clinical genomics laboratory in Irvine, CA
more...
03.08.2010 Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
more...
15.07.2010 Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
more...
23.06.2010 Santaris Pharma A/S and miRagen Therapeutics, Inc. form strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease
more...
15.06.2010 Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
more...
12.06.2010 Horizon Pharma, Inc. Announces Phase 3 Study of LODOTRA® Demonstrates 12-Month Sustained Efficacy in Rheumatoid Arthritis
more...
09.06.2010 Horizon Pharma Announces LODOTRA® and HZT-501 Data to be Presented at the European League Against Rheumatism (EULAR) Annual Congress
more...
07.06.2010 Pieris AG Appoints Chief Scientific Officer
more...
07.06.2010 Action Pharma obtains encouraging preliminary results in a phase II clinical trial with AP214
more...
04.06.2010 Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
more...
02.06.2010 Nabriva initiates Phase II of pleuromutilin antibiotic BC-3781
more...
26.05.2010 7TM Pharma receives milestone payment from asthma and allergy collaboration
more...
26.05.2010 Horizon Pharma, Inc. Announces FDA Acceptance of HZT-501 New Drug Application for Filing
more...
19.05.2010 Horizon Pharma, Inc. Presents Interim Results from a Pilot Clinical Study Evaluating LODOTRA® in the Treatment of Severe Nocturnal Asthma
more...
30.04.2010 NeurogesX Enters $40 Million Royalty Financing Agreement with Cowen Healthcare Royalty Partners
more...
30.04.2010 Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
more...
29.04.2010 New Study Demonstrates Patients with High-Risk MammaPrint Profile Benefit from Chemotherapy
more...
26.04.2010 Santaris Pharma A/S advances RNA-targeted drug development candidate against PCSK9, an important new target for the treatment of high cholesterol
more...
22.04.2010 A potential new treatment for cancer supportive care and gastrointestinal diseases
more...
20.04.2010 Agendia and Ferrer inCode Expand MammaPrint® Distribution Agreement to Latin America
more...
01.04.2010 Horizon Therapeutics and Nitec Pharma complete merger and combine businesses
more...
24.03.2010 Agendia Launches BluePrint™ Expanding Breast Cancer Product Offering
more...
17.03.2010 Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 12 Cancer Drugs Tested, 20 Leading U.S. Cancer Centers Involved
more...
08.03.2010 Action Pharma reports positive results in a proof of concept phase IB
study in obese human volunteers treated with small molecule oral once-daily AP1030 targeted for
type II diabetes associated with obesity
more...
02.03.2010 FDA Approves Exalgo(tm) Extended-Release Tablets
more...
09.02.2010 Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
more...
04.02.2010 NeurogesX Announces Management Team Promotions
more...
04.02.2010 7TM Pharma successfully conducts clinical phase I trial with its second generation CB1 receptor antagonist
more...
20.01.2010 7TM Pharma successfully conducts clinical phase I trial with its second generation CB1 receptor antagonist
more...
04.01.2010 Pieris appoints a New CEO
more...
17.12.2009 Agendia – FDA Broadens Clearance for Agendia’s MammaPrint®
more...
04.12.2009 New data show breakthrough microRNA-targeted therapy developed using Santaris Pharma A/S proprietary LNA technology holds promise as new treatment for Hepatitis C
more...
16.11.2009 NeurogesX Receives FDA Approval of Qutenza™ (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
more...
29.10.2009 Nabriva Therapeutics raises Euro 15 Million (USD 22 Million)
more...
28.10.2009 Santaris Pharma A/S expands executive team, appoints Chief Medical Officer and Chief Business Officer to advance proprietary RNA-target drug development programs
more...
20.10.2009 Action Pharma in new phase II clinical trial
more...
09.10.2009 Pieris reports preclinical progress of its next generation VEGF antagonist
more...
09.10.2009 Medigene successfully completes patient recruitment into EndoTAG™-1 Phase II breast cancer trial
more...
29.09.2009 MediGene Signs Agreement with Solvay for the Commercialization of Veregen® in Germany, Austria, and Switzerland
more...
15.09.2009 New collaboration and breakthrough advancements in RNA-based drug development programs lead Santaris Pharma A/S to establish US operations
more...
15.09.2009 Pieris AG enters into Anticalin Collaboration with Allergan, Inc.
more...
09.09.2009 MediGene AG Receives Marketing Authorization for Veregen® in Germany
more...
02.09.2009 Nitec Pharma reports positive and highly significant Phase III results from CAPRA-2 study of LODOTRA™ in RA
more...
24.08.2009 Santaris Pharma A/S forms strategic alliance with Shire plc to develop RNA-based medicines for the treatment of rare genetic disorders
more...
10.08.2009 Ikaria® to in-licence worldwide rights to investigational portfolio from Fibrex Medical
more...
07.08.2009 MediGene Reports First Six Months of 2009: Revenue Increased, Result Improved
more...
31.07.2009 Cytos; CYT003-QbG10 monotherapy for the treatment of allergic rhinoconjunctivitis is safe and efficacious in phase IIb study
more...
24.07.2009 Santaris Pharma; Original paper: microRNAs in CNS disorders published in Neuromol Med
more...
24.07.2009 Neurogesx Announces Preliminary Results of FDA-Requested Qutenza™ Study
more...
23.07.2009 Nabriva Therapeutics initiates Clinical Phase I trial of pleuromutilin antibiotic BC-3781
more...
20.07.2009 Santaris Pharma presents at the World Summit of Antivirals
more...
17.07.2009 NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
more...
14.07.2009 Santaris Pharma; Advanced Access publication in Nucleic Acid Research on silencing of miRNA-155 in mice
more...
09.07.2009 Santaris Pharma publishes interim report for firs half of 2009
more...
06.07.2009 Coapt Systems, Inc. Launches Hydrelle™ a New, FDA-Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction and Greater Patient Comfort
more...
01.07.2009 CombinatorX and Neuromed Sign Merger Agreement
more...
29.06.2009 NeurogesX Added to Russell 3000 Index
more...
24.06.2009 Cytos Biotechnology reports biochemical findings from phase IIa study with hypertension vaccine CYT006-AngQb
more...
23.06.2009 MediGene Concludes Agreement with Juste for the Commercialization of Veregen® in Spain and Portugal
more...
23.06.2009 Agendia’s Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
more...
22.06.2009 NeurogesX and Astellas Enter Commercialization Agreement for Qutenza™
more...
12.06.2009 CombinatoRx Presents Full Data on Synavive Phase 2 Knee OA Trial at EULAR 2009
more...
11.06.2009 Cytos Biotechnology initiates combined phase I/IIa study with a novel anti-interleukin-1 beta vaccine in patients with type II diabetes mellitus
more...
04.06.2009 Santaris; LNA-based HIF-1 alpha inhibitor shows early signs of clinical benefit
more...
03.06.2009 Santaris Pharma Director appointed Adjunct Professor in RNA Biology
more...
03.06.2009 CombinatoRx Announces Positive Results for Aligned-Release Synavive
more...
02.06.2009 NeurogesX Receives FDA Orphan Drug Designation for Qutenza™ for Treatment of Postherpetic Neuralgia
more...
27.05.2009 CombinatorX Reports Positive Phase 2 Trial Results for CRx-401
more...
26.05.2009 MediGene: Presentation of EndoTAG™-1 and oHSV Results at the 2009 ASCO Annual
more...
20.05.2009 FDA Grants Orphan Drug Designation for MediGene’s Drug Candidate EndoTAG™-1
more...
06.05.2009 CombinatorX Announces Oncology Collaboration
more...
04.05.2009 CombinatoRx Collaborator Fovea Reports Encouraging Clinical Results with CombinatoRx-Derived Combination Drug Candidate
more...
21.04.2009 Cytos Biotechnology initiates phase IIa study with CYT003-QbG10 monotherapy in patients with allergic asthma bronchiale
more...
07.04.2009 MediGene: USPTO Grants Extension of a Patent on Veregen®
more...
24.03.2009 Agendia to Present at BioCentury’s Future Leaders in the Biotech Industry Conference
more...
20.03.2009 Another LNA-based RNA Inhibitor Enters Clinical Trials
more...
19.03.2009 NeurogesX‘ Qutenza™ (NGX-4010) Receives Positive Committee Recommendation in European Union
more...
05.03.2009 Agendia Appoints Seasoned Diagnostic Executive Albert A. Luderer to Supervisory Board
more...
27.02.2009 NITEC PHARMA COMPLETES RECRUITMENT IN US PHASE III TRIAL FOR LODOTRA™
more...
18.02.2009 Agendia Publishes Direct Evidence that MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
more...
12.02.2009 Action Pharma’s CEO awarded the Novo Nordisk Prize 2009
more...
11.02.2009 Agendia Appoints VP of Business Development
more...
11.02.2009 Cytos Biotechnology Announces Full Year 2008 Financial Results and Annual Highlights
more...
10.02.2009 Santaris Pharma A/S: Enzon announces IND acceptance for its Survivin antagonist
more...
09.02.2009 Action Pharma recruits Executive Vice President of Business Development to lead the commercialization of the clinical and preclinical drug candidates
more...
05.02.2009 MediGene to be listed on TecDAX Index
more...
03.02.2009 Pieris reports development progress for Anticalin® PRS-050, a next generation VEGF antagonist
more...
02.02.2009 Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines
more...
27.01.2009 Intercell was awarded Technology Pioneer by the World Economic Forum in Davos
more...
16.01.2009 MediGene: Presentation of Clinical Data Obtained with EndoTAG™-1 for the Treatment of Pancreatic Cancer and with the Oncolytic Virus NV1020 for the Treatment of Metastasized Colorectal Carcinoma at the ASCO GI Meeting
more...
15.01.2009 7TM Pharma closes a financing round and sells certain early stage discovery assets and technology to OSI Pharmaceuticals
more...
13.01.2009 Cytos Biotechnology presents analysis of patient diaries including six month follow-up data from phase II study with CYT003-QbG10 monotherapy for the treatment of allergic diseases
more...
12.01.2009 Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines
more...
07.01.2009 Nitec Pharma's new Rheumatoid Arthritis Treatment, Lodotra™, recommended for European Regulatory Approval
more...
05.01.2009 Pfizer execute s commercial license agreement for novel human vaccines based on Cytos Biotechnology’s Immunodrug ™ technology
more...
22.12.2008 MediGene secures committed standby equity line of up to 25 million Euro
more...
19.12.2008 NeurogesX Announces FDA Acceptance to Review New Drug Application for NGX-4010 to Treat Post-Herpetic Neuralgia
more...
12.12.2008 Agendia’s MammaPrint® Predicts to Neoadjuvant Chemotherapy in Breast Cancer
more...
11.12.2008 Intercell AG wins the Scrip Award for Biotech Company of the year
more...
09.12.2008 CombinatoRx Presents New Data on B-Cell Malignancy Programs
more...
27.11.2008 MediGene: European Patent Office decides to grant new European Patent for Veregen®
more...
22.10.2008 NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
more...
20.10.2008 MediGene Reports Positive Final Results from EndoTAG(TM)-1 Phase II Study in Pancreatic Cancer
more...
17.10.2008 Medigene: RhuDex(TM) to be Examined in Further Laboratory Tests
more...
15.10.2008 New class of drug candidates developed by Santaris Pharma can potently counteract disease-associated microRNAs
more...
01.10.2008 MediGene Spins Out mTCR Programme - Independent Company Immunocore Limited Founded
more...
29.09.2008 Nitec Pharma AG secures funding of CHF 24M from TVM and Deutsche Bank
more...
29.09.2008 Medigene Clinical data for EndoTAG(TM)-1 to be presented at two further medical conferences (DVGS, UEGW)
more...
21.09.2008 Coapt Sytems Launches FDA Cleared Novielle Voice(TM) For Restoration Of Voice Loss
more...
16.09.2008 MediGene reports positive 12-month survival data for EndoTAG(TM)-1 from Phase II pancreatic cancer study 
more...
15.09.2008 Medigene Appoints Dr Hans Joachim Bochtler as Vice President Clinical Research & Development
more...
09.09.2008 New clinical data for EndoTAG(TM)-1 to be presented at
more...
04.09.2008 Agendia Launches TargetPrint© for Breast Cancer Patients
more...
02.09.2008 Fibrex Medical Reports Positive Phase II Results for FX06
more...
02.09.2008 7TM Pharma has initiated Phase I/IIa clinical trial with TM30339 for the treatment of obesity and related metabolic disorders
more...
19.08.2008 European Patent Granted on the Application of Anti-L1 Antibodies in Cancer Therapy
more...
31.07.2008 MediGene Sells Licensee Rights to the Drug Oracea® to Galderma
more...
16.07.2008 Wacker validates scalability of Anticalin® production with E.coli secretion technology and will produce Pieris first clinical candidate PRS-050
more...
25.06.2008 Action Pharma presents pre-clinical data for treatment of Type 2 diabetes
more...
24.06.2008 MediGene Achieves Positive Results with RhuDex® in Clinical Phase IIa Trial
more...
24.06.2008 FierceBiotech Names Santaris Pharma as One of the "Fierce 15" Biotech Companies of 2008
more...
18.06.2008Santaris Pharma appoints Søren Tulstrup as new President & CEO
more...
16.06.2008 Action Pharma launches a Phase II clinical trial
more...
12.06.2008 Nitec to present Lodotra™ 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris
more...
10.06.2008 IMI Intelligent Medical Implants AG announces the appointment of Dr. Stephen J McCormack as Chief Executive Officer
more...
13.05.2008 Intercell AG to acquire Iomai Corporation to expand late stage product pipeline and strengthen leadership in vaccine innovation
more...
24.04.2008 European Regulatory Authority (EMEA) Recommends Granting of Marketing Authorization for MediGene's Drug Oracea®
more...
24.04.2008 Intercell was awarded "The Vaccine Industry Excellence Award" in the category "Best New Therapeutic Vaccine" for its therapeutic Hepatitis C (HCV) vaccine candidate
more...
21.04.2008 Intercell - Strong alliance to fight fungal infections
more...
16.04.2008 7TM Pharma receives milestone payment from asthma and allergy collaboration
more...
16.04.2008 Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
more...
15.04.2008 Intercell's investigational vaccine against Japanese Encephalitis shows excellent safety and immunogenicity in Phase II trials in children
more...
07.04.2008 MediGene Presents Details of the Excellent Clinical Efficacy Data Obtained with EndoTAG(TM)-1 in the Indication Pancreatic Carcinoma
more...
02.04.2008 MediGene Extends Protection for its Innovative EndoTAG(TM) Technology by Another European Patent
more...
27.03.2008 Pieris raises € 25 M (US$ 38 M) in Series B financing round
more...
12.03.2008 CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results in Psoriasis
more...
10.03.2008 7TM Pharma enters into drug discovery collaboration with Dr. Reddy’s on selected drug targets
more...
03.03.2008 FIRST PROFITABLE YEAR IN INTERCELL'S HISTORY – CLEAR GROWTH IN REVENUES AND PROFITABILITY EXPECTED FOR 2008
more...
29.02.2008 Licensure application for JE vaccine submitted to Therapeutic Goods Administration in Australia
more...
06.02.2008 7TM Pharma announces the selection of a new pre-clinical development candidate, TM38837, for treatment of obesity and Type 2 diabetes
more...
26.01.2008 Blind patients see the light with retinal implant system from Switzerland's IMI
more...
17.01.2008 Action Pharma raises EUR 15 million from investors
more...
19.12.2007 GlaxoSmithKline and Santaris Pharma enter global R&D alliance to discover, develop and commercialise RNA antagonists as novel antivirals
more...
18.12.2007 Santaris raises €20 million of new equity
more...
16.12.2007 Intercell Receives Milestone Payment From Merck & Co. Inc Triggered By Initiation Of Phase II Clinical Trial of Investigational Vaccine to Prevent S.aureus Infection
more...
06.12.2007 Intercell Submits Marketing Authorization Application (MAA) to EMEA for Licensure of Japanese Encephalitis Vaccine
more...
04.12.2007 SSI, Intercell and Areas announce start of clinical trial for novel vaccine candidate against TB
more...
03.12.2007 Intercell´s clinical data on Japanese Encephalitis vaccine published in “The Lancet”
more...
19.11.2007 Agendia B.V.; Time "Best Inventions Of 2007" Cancer's Crystal Ball
(page 61)
more...
16.11.2007 Pfizer to Acquire Coley Pharmaceutical Group
more...
30.10.2007 Pieris and Pepscan to identify GPCR-specific Anticalins® using CLIPS™ protein mimicry technology
more...
09.10.2007 NeurogesX Expands Senior Management Team
more...
10.09.2007 MediGene Raises € 15,6 Million in Private Placement with Santo Holding GmbH
more...
05.09.2007 MediGene Completes Patient Recruitment for Clinical Trial of Cancer-Killing Virus NV1020
more...
05.09.2007 Pieris validates the use of Anticalins® as ophtalmologic biotherapeutics
more...
04.09.2007 NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
more...
31.08.2007 MediGene: European Approval Procedure for the Six-Months Dosage of Cancer Drug Eligard® Successfully Completed
more...
28.08.2007 Agendia BV raises €25 Million ($34M) and Receives Second FDA Clearance
more...
21.08.2007 Intercell’s therapeutic Hepatitis C vaccine meets primary endpoints in Phase II interim analys
more...
16.07.2007 First child vaccinated with Intercell Japanese Encephalitis (JE) Vaccine in India - Pediatric Phase II clinical trial started
more...
10.07.2007 Pieris progresses proprietary asthma program: validation of pulmonary delivery of Anticalin® -based protein product candidate
more...
10.07.2007 Agendia BV; Gene expression profile determines prognosis of stage II colon cancer patients
more...
04.07.2007 Santaris Pharma consortium awarded E1.35m by Denmark's Advanced Technology Foundation for development of the first microRNA medicine
more...
02.07.2007 Intercell and Novartis form world-leading strategic partnership to drive vaccines innovation
more...
07.06.2007 7TM Pharma raises DKK 123 million in financing round
more...
30.06.2007 CombinatoRx - Old Drugs In, New Ones Out
more...
21.05.2007 CombinatoRx Has a Rich Pipeline
more...
18.05.2007 Intercell AG; Staphylococcus aureus vaccine development on track - safe and immunogenic in Phase I clinical trials
more...
25.04.2007 Cytos enters exclusive license agreement with Novartis to develop, manufacture and commercialize novel vaccine for treatment of nicotine addiction
more...
18.04.2007 Santaris Pharma presents positive preclinical data on SPC 2996 at the American Association for Cancer Research
more...
29.03.2007 Pieris demonstrates potent anti-tumor activity of a VEGF-specific Anticalin® in preclinical studies
more...
26.01.2007 Agendia's MammaPrint® breast cancer prognosis test cleared by U.S. Food and Drug Administration (FDA)
more...
26.01.2007 FDA approves Enzon IND for Santaris Pharma’s Second New Cancer Drug Company receives $5m milestone payment from Enzon Pharmaceuticals
more...
23.01.2007 Dr Walter Wenninger appointed to Santaris Pharma Board
more...
28.11.2006 Santaris Pharma awarded Ernst&Young Entrepreneur of the Year 2006
more...
25.10.2006 Pieris confirms in vivo activity pf potent VEGF-specific Anticalin®
more...
18.10.2006 NeurogesX Phase 3 Study in Post-Herpetic Neuralgia Meets Primary Endpoint
more...
13.10.2006 Intercell AG wins European Biotechnica Award 2006
more...
12.10.2006 Claus Braestrup, CEO of Lundbeck, appointed to Santaris Pharma Board
more...
28.09.2006 Nitec Pharma Reports Positive Phase III Results and Filing in EU for LODOTRA(tm)
more...
06.09.2006 Agendia's MammaPrint® breast cancer prognosis test validated by an independent international consortium
more...
27.07.2006 Enzon and Santaris Pharma enter into Global Collaboration to Develop Novel Cancer Therapeutics
more...
31.05.2006 Positive results for Intercell's Japanese Encephalitis virus vaccine in pivotal clinical trail
more...
24.03.2006 CombinatoRx Reports Positive Results for CRx-170 in Phase 2 Proof-of-Concept Asthma Clinical Trial
more...
24.03.2006 CombinatoRx Announces Closing of $48.0 Million Private Placement
more...
21.03.2006 Coley Pharmaceutical Group Announces Top-line Data from a Clinical Study of Actilon(tm) for Hepatitis C
more...
31.01.2006 Cyberkinetics Provides Update on Braingate (TM) System Pilot Clinical Trials: Total of Four Participants Have Enrolled in Ongoing Trials of BrainGate System
more...
31.01.2006 Orphan Drug Status for Intercell's JEV Vaccine
more...
30.01.2006 CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 Study Results in Hand Osteoarthritis
more...
03.10.2005 CombinatorX and Angiotech sign agreement to apply CombinatorX's pipeline and technology to the field of interventional medicines
more...
09.08.2005 Intercell AG - Start of Phase III clinical trials for Japanese Encephalitis Vaccine now approved by major European authorities - EMEA supports Intercell's Clinical Development Strategy
more...
01.08.2005 Coley Pharmaceutical Group Sets Price for Public Offering
more...
14.06.2005 $ 6.6 million R&D grant from US NIH for Intercell to develop biodefense
vaccines
more...
09.06.2005 Robert L. Bratzler, CEO of Coley Pharmaceutical Group, Honored with The
Oliver R. Grace Award by the Cancer Research Institute
more...
14.05.2005 Cytos AG - Vaccine to treat nicotine addiction achieves proof of efficacy
more...
20.04.2005 Coley Pharmaceutical Group Files Registration Statement for Proposed Initial Public Offering
more...
12.04.2005 Pieris Proteolab AG und Syngenta Biopharma Collaborate to Develop
Anticalins
more...
04.04.2005 Cyberkinetics Gives Update on BrainGate Clinical Trial
more...
04.04.2005 Cyberkinetics Receives Neuropart 510K Clearance; Acute Neural Monitor is Company's First Commercial Clinical Product
more...
01.04.2005 Cytos Biotechnology and Medarex expand their collaboration for new drug targets
more...
02.03.2005 Intercell Shares begin trading on the Vienna Stock Exchange
more...
01.02.2005 Die Schweizer Glycart Biotechnology AG verbessert die Wirksamkeit von therapeutischen Antikörpern
more...
13.12.2004 CombinatorX files registration statement for proposed initial public offering
more...
13.12.2004 Intercell AG and SciGen Ltd. sign an exclusive agreement for the development of a therapeutic Hepatitis B vaccine
more...
07.12.2004 MediGene Successfully Completes Pivotal Clinical Phase II Trials of Polypehnon® Ointment for the Treatment of Genital Warts
more...
02.12.2004 Cytos Biotechnology announces change in Executive Board
more...
02.12.2004 Coley Pharmaceutical GmbH Receives Award at the Future Congress 2004 "Benchmark NRW"
more...
02.12.2004 Cytos Biotechnology initiates a phase II clinical trial with its Immunodrug™ candidate CYT005-AllQbG10 for treatment of allergy
more...
26.10.2004 Xantos Biomedicine signs service agreement with Serono
more...
07.10.2004 Cyberkinetics Neurotechnology Systems, Inc. completes merger, name change and reincorporates in Delaware
more...
28.09.2004 Coley Pharmaceutical Group Raises $25 Million in Private Financing
more...
21.09.2004 Cytos Biotechnology awarded the third prize of the European BioTechnica Award 2004
more...
21.09.2004 Coley Pharmaceutical Group Announces $16.9 Million Research Contract From NIH for Development of New Vaccine Adjuvants for Biodefense
more...
16.09.2004 Clinical Trial advances Cytos Biotechnology's second Immunodrug™ platform
more...
15.09.2004 Prof. Arne Skerra, Dr. Martin Pöhlchen, and Dr. Steffen Schlehuber Nominated for the German Future Prize (Deutscher Zukunftspreis) 2004 of the German Federal President
more...
13.09.2004 Xantos secures additional finance of Euro 4 million (USD 4.8 million)
more...
02.09.2004 Xantos Biomedicine integrates Evotec Technologies high content imaging reader OperaTM into its cDNA transfection technology XantosScreenTM
more...
31.08.2004 Intercell AG Announces Extended Collaboration with Aventis on the Development of Bacterial Vaccines
more...
28.07.2004 Cyberkinetics named among top 15 emerging Life Science Companies of 2004
more...
20.07.2004 Intercell reaches primary endpoint in successful Phase II Hepatitis C trial
more...
23.06.2004 Intercell AG and Solvo Biotechnology Inc. Sign Licence Agreement
more...
24.05.2004 Applied Phenomics enters collaboration with Xantos Biomedicine in histology-based target validation
more...
17.05.2004 Develogen AG and Peptor Ltd shareholders approve merger
more...
07.05.2004 PIERIS receives € 2 million grant from German Ministry of Education and Research (BMBF)
more...
28.04.2004 Glycart Biotechnology Appoints William J. Jenkins to Board of Directors
more...
17.03.2004 Intercell and Statens Serum Institut Sign Cooperation and License Agreement to Develop Tuberculosis Vaccine
more...
10.03.2004 CombinatorX raises $30 million in third Venture Capital Round
more...
09.03.2004 Genencor Chairman Joins NeurogesX Board
more...
03.03.2004 Intercell Acquires Manufacturing Plant in Scotland
more...
17.02.2004 Aventis and Intercell sign collaboration and licence agreement to develop bacterial vaccines
more...
17.02.2004 Exelixis Publishes World’s Most Comprehensive Collection of Functional Gene Knockouts in an Multicellular Organism
more...
09.02.2004 Roche and Xantos Biomedicine AG sign agreement for compound-target validation
more...
17.02.2004 Aventis and Intercell sign collaboration and licence agreement to develop bacterial vaccines
more...
17.02.2004 Exelixis Publishes World’s Most Comprehensive Collection of Functional Gene Knockouts in an Multicellular Organism
more...
09.02.2004 Roche and Xantos Biomedicine AG sign agreement for compound-target validation
more...
09.02.2004 ARTEMIS Pharmaceuticals and AVENTIS Pharma R&D Sign Agreements Related to Mouse Genetics
more...
03.02.2004 Cytos enters agreement to supply Alzheimer’s ImmunodrugTM candidate for early clinical development studies
more...
22.01.2004 Sequenom collaborates with Health Protection Agency to apply MASSARRAY ™ Technology in Pathogen analysis
more...
13.01.2004 Coley Pharmaceutical Group initiates phase 1 clinical trials of Actilon TM for chronic hepatitis C infection
more...
07.01.2004 Cyberkinetics announces management additions in clinical operations and applications development
more...
23.12.2003 Memory Pharmaceuticals Corp. files Registration Statement for Initial Public Offering of common stock
more...
23.12.2003 AXXIMA appoints Yoram Karmon as new president and CEO
more...
26.11.2003 Glycart Biotechnology closes $ 313.6m private financing round
more...
18.11.2003 Pieris announces breakthrough in AnticalinR Technology
more...
13.11.2003 Peptor and Develogen announce intentions to merge
more...
27.10.2003 Healthgate completes acquisition of EBM Solutions, Inc
more...
20.08.2003 Apovia announces exclusive licence for otitis media vaccine from National Institute of Health
more...
18.09.2003 Roche and Memory Expand Strategic Alliance in CNS
more...
10.09.2003 Novartis executes Commercial Licence Agreement for Immunodrugs TM against neurodegenerative disease
more...
10.09.2003 Develogen and Evotec OAI announce a strategic drug discovery and development alliance for metabolic deseases.
more...
02.09.2003 Collaboration Agreement between Corixa and Apovia AG
more...
01.09.2003 Coley Pharmaceutical Group Announces $35 Million Private Financing
more...
17.07.2003 Intercell AG Vienna raises $34 million
10.07.2003 SEQUENOM announces genetic discovery collaboration with Bristol-Myers Squibb
more...
09.07.2003 Cyberkinetics, Inc. raises $4.3 million to develop its Braingate neural interface device
more...
01.07.2003 Cytos’ Immunodrug for smoking addiction successfully completes phase I clinical trial
06.05.2003 Exelixis Announces Departure of Chief Financial Officer
more...
28.04.2003 Cytos and Novartis extend collaboration agreements
28.04.2003 SEQUENOM Customers Develop Two Novel Applications for MassARRAY(TM) Platform
23.04.2003 Cytos Immunodrug™ for smoking addiction enters phase I clinical trial
10.04.2003 DeveloGen AG und das Max-Planck-Institut für biophysikalische Chemie erhalten den Kooperationspreis des Landes Niedersachsen 2002
02.04.2003 SEQUENOM and Isis Pharmaceuticals Collaborate to Discover Genetic Variation in Antisense Drug Target Regions
31.03.2003 Exelixis Files IND for First Proprietary Anticancer Compound
more...
06.03.2003 SEQUENOM Publishes Gene Expression Analysis Method
03.03.2003 Memory Pharmaceuticals compound MEM1414 to be developed by Roche for treatment of Alzheimer's disease
more...
17.02.2003 EBM Solutions, Inc. acquires Help4Life, Inc.
more...
13.02.2003 Coley Pharmaceutical Group's CpG 7909 Active in Immunocompromised Patients
more...
21.01.2003 Coley Pharmaceutical Group Receives Milestone Payment From Aventis Pharma
more...
17.01.2003 DeveloGen and Scientists from IPK Gatersleben Publish Data on Key Trigger for Regenerating Insulin Producing Cells
15.01.2003 Xantos Biomedicine AG appoints Ulrich Brinkmann as Chief Scientific Officer
14.01.2003 SEQUENOM Adds Former Amgen President and COO Harry Hixson to Board of Directors
09.12.2002 Axxima receives one million Euro in funding from the BMBF "Proteomics" program
more...
02.12.2002 Axxima founder Axel Ullrich awarded King Faisal International Prize worth 200,000 US dollars
more...
31.10.2003 PIERIS Proteolab AG closes €12 million Financing Round
08.10.2002 Xantos Biomedicine AG Expands Its High Quality Full Length Human cDNA Collection - Target identification and validation is greatly accelerated
more...
03.10.2002 Health Net, Inc. (NYSE:HNT) announced today that it has partnered with EBM Solutions, Inc., a leading provider of evidence-based guidelines and care management applications, to provide its contracted physicians and health plan members with evidence-based resources regarding health care options and treatment plans
01.10.2002 Xantos Biomedicine AG announces the appointment of David Chilvers as Chief Business Officer - Paul Nicholson joins Board as Chairman
more...
19.09.2002 COMBINATORx RAISES $40 MILLION
16.09.2002 APOVIA initiates MalariVax™ Phase I clinical trials - Clinical Trials for Malaria Vaccine start at the University of Maryland and in South Wales, UK
more...
03.09.2002 DeveloGen appoints Dr. Klaus Brandau as Chairman of the Supervisory Board
26.08.2002 MyDocOnline Provides EBMSolutions' Application To Enhance Patient-Physician Communication
more...
22.07.2002 BioFocus and Axxima enter Drug Discovery Collaboration
more...
10.06.2002 ARTEMIS Pharmaceuticals and MERCK collaborate to develop customized mouse models.
more...
23.04.2002 CombinatorX and SOSEI launch colloboration
22.04.2002 APOVIA raises € 19 Million in Private Financing Round - New Appointments to Supervisory Board
more...
17.04.2002 DeveloGen Names Dr. Guenther Karmann as CEO
< back